Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study

Gasslitter, Irina; Kirsten, Natalia; Augustin, Matthias; Torz, Kaspar; Mrowietz, Ulrich; Eyerich, Kilian; Puig, Lluís; Hoetzenecker, Wolfram; Schütz-Bergmayr, Martina; Weger, Wolfgang; Wolf, Peter; Reider, Norbert; Ratzinger, Gudrun; Papageorgiou, Karolina; Meier, Thomas; Maul, Julia‐Tatjana; Anzengruber, Florian; Navarini, Alexander A.

doi:10.1007/s00403-019-01907-y

Cited by 43 publications

(30 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is less compared to three other retrospective studies in which patients receiving ixekizumab as second IL17A-blocker reached a PASI 75 response at week 12 in 71% [5], 81% [4], or even 100% [3]. In another retrospective study, 50% PASI 75 response at week 12 to ixekizumab as second IL17Ablocker was comparable to our study [8]. Until now, to our knowledge, only one study reported PASI 75 responses after 24 weeks of ixekizumab as second IL17A-blocker, which were reached by a higher proportion of patients (80%), compared to 42.1% in our study [4].…”

Section: Discussioncontrasting

confidence: 89%

Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab

Amschler

Phillip²,

Mohr³

et al. 2020

Dermatology Online Journal

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 89%

Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab

Amschler

Phillip²,

Mohr³

et al. 2020

Dermatology Online Journal

View full text Add to dashboard Cite

“…Of note, there were a substantial number of intraclass switches in anti‐IL‐17 drug from secukinumab to ixekizumab, as well as a number of switches to a new class of anti‐IL‐23‐p19 antibodies (guselkumab, risankizumab and tildrakizumab) (Table S13). However, intraclass switching in IL‐17 inhibitors is not uncommon, as it may restore clinical efficacy 33 . Overall, the rate at which a previously administered drug was restarted (after an interval of at least 12 weeks after the regularly scheduled administration as defined in the methods) ranged from 2·6% to 19·0% for etanercept, adalimumab, secukinumab, ustekinumab and ixekizumab (Table S13).…”

Section: Resultsmentioning

confidence: 99%

Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis*

et al. 2021

View full text Add to dashboard Cite

Summary Background Drug survival rates reflect efficacy and safety and may be influenced by the availability of alternative treatment options. Little is known about time‐dependent drug survival in psoriasis and the effect of increasing numbers of biologic treatment options. Objectives To determine whether drug survival is influenced by the availability of treatment options and by factors such as gender, psoriatic arthritis or previous biologic treatment. Methods This observational, retrospective, multicentre cohort study analysed data from patients registered in the Austrian Psoriasis Registry (PsoRA) who were treated with biologics between 1 January 2015 and 30 November 2019. Results A total of 1572 patients who received 1848 treatment cycles were included in this analysis. The highest long‐term Psoriasis Area and Severity Index improvement was observed after treatment with ixekizumab, followed by ustekinumab and secukinumab, adalimumab and etanercept. Overall, ustekinumab surpassed all other biologics in drug survival up to 48 months. However, when adjusted for biologic naïvety, its superiority vanished and drug survival rates were similar for ixekizumab (91·6%), secukinumab (90·2%) and ustekinumab (92·8%), all of them superior to adalimumab (76·5%) and etanercept (71·9%) at 12 months and beyond. Besides biologic non‐naïvety (2·10, P < 0·001), the introduction of a new drug such as secukinumab or ixekizumab (relative hazard ratio 1·6, P = 0·001) and female gender (1·50, P = 0·019) increased the risk of treatment discontinuation overall, whereas psoriatic arthritis did not (1·12, P = 0·21). Conclusions The time‐dependent availability of drugs should be considered when analysing and comparing drug survival. Previous biologic exposure significantly influences drug survival. Women are more likely to stop treatment.

show abstract

“… 59 Some of these non-responder patients can be successfully switched between IL-17A inhibitors – perhaps as a consequence of reinduction – but others become resistant. 60 The broader blockade of brodalumab may account for its high efficacy and speed of response, but quick relapses have been reported on treatment discontinuation; increased levels of active IL-17 cytokines on blockade of their common receptor subunit IL-17RA might provide a mechanistic explanation. 61 Dual inhibition of IL-17A and IL-17F represents a novel approach that has proved to be effective in multiple models of disease, in both preclinical and clinical studies.…”

Section: Discussionmentioning

confidence: 99%

Dual inhibition of IL-17A and IL-17F in psoriatic disease

Iznardo

Puig

2021

Therapeutic Advances in Chronic Disease

Self Cite

View full text Add to dashboard Cite

Psoriasis and psoriatic arthritis are chronic immune-mediated disorders with involvement of interleukin (IL)-17 cytokines in their pathogenesis. IL-17A has been considered to be the most biologically active, but IL-17F is also over-expressed in skin and synovial tissues of patients with these diseases. Many therapeutic advances have been made in the past years, but some needs remain unmet. Dual inhibitor and bispecific antibodies simultaneously targeting IL-17A and IL-17F could provide better disease control. Herein we review current evidence on bimekizumab and sonelokimab. The antigen-binding site of bimekizumab neutralizes both IL-17A and IL-17F; phase I, II, and III studies have demonstrated its efficacy and safety in psoriasis and psoriatic arthritis. Sonelokimab is a trivalent nanobody targeting IL-17A and IL-17F; phase I and II studies with this molecule have yielded promising results in psoriasis.

show abstract

Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study

Cited by 43 publications

References 6 publications

Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab

Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab

Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis*

Dual inhibition of IL-17A and IL-17F in psoriatic disease

Contact Info

Product

Resources

About